Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

By E. Bugianesi, N. Leone, E. Vanni, Giulio Marchesini, F. Brunello, P. Carucci, A. Musso, P. De Paolis, L. Capussotti, M. Salizzoni and 1 more. Gastroenterology, 2002

1,293 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/980c520f7d926844048cb1de0e77a47816387dd4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Z. Younossi
2. J. Clark
3. C. Day
4. A. Diehl
5. E. Brunt
6. R. Lopez
7. Giulio Marchesini
8. S. Harrison

In Hepatology

1. J. Clark
2. R. Lopez
3. Z. Younossi
4. E. Brunt
5. A. Diehl
6. M. Pinzani
7. C. Day
8. Megan H. Bair-Merritt

Citations in the corpus

• Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes (2008, methodology): “19 The diagnosis of the metabolic syndrome was carried out according to Adult Treatment Panel III criteria,20 and based on the presence of three or more of the following criteria: (1) fasting glucose 110 mg/dL; (2) central obesity (waist circumference 102 cm (men) and 88 cm (women); (3) arterial pre”
• Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms (2005, background): “There is growing concern regarding NAFLD due to its high prevalence in the general population and its potential for progression to cirrhosis [1], terminal liver failure [2] and hepatocellular carcinoma [3].”
• Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection (2010, background): “Multiple retrospective studies have been done evaluating HCC in the setting of CC, which support the notion that NASH accounts for a large proportion of CC and can progress to HCC.(42,49,55,56) In 2002, Bugianesi et al.”
• Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease (2010, neutral): “013 NAFLD activity score 4 (3-5) 4 (3-5) 3 (2-4) 4 (3-5) 3 (2-4) 0.”
• The prevalence and etiology of elevated aminotransferase levels in the United States (2003, background): “Regardless of the underlying cause, individuals with cirrhosis are at risk for developing serious liver-related complications, including hepatocellular carcinoma”
• The Epidemiology of Nonalcoholic Fatty Liver Disease in Adults (2006, background): “Currently, prospective studies of NAFLD are limited by the small numbers of patients overall, a very small percentage of whom develop cirrhosis or HCC.3,66–68”
• Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up (2010, neutral): “No-NASH (1-2) Alive (24) 12 2 0 0 10 Dead (8) 2 1 1 1 2 1 Border line (3-4) Alive (18) 10 3 0 0 5 Dead (15) 3 6 3 3 0 NASH (5-8) Alive (29) 11 12 2 1 3 Dead (24) 5 10 3 4 2”
• Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. (2012, background): “When associated with NAFLD, HCC is often moderately or well differentiated and occurs as solitary large mass [42,89].”
• Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta‐analysis (2011, methodology): “if data were available, we evaluated the diagnostic accuracy of the following parameters: (1) parenchymal brightness, (2) liver-to-kidney contrast, (3) deep beam attenuation, (4) bright vessel walls, and (5) gallbladder wall definition.”
• The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis (2010, background): “Emergent data suggest that NAFLD is a key factor linking obesity and HCC.(11-14) It is estimated that nearly two-thirds of obese people have some form of fatty liver, ranging from steatosis to NASH.”